Moreover, because most patients with CDH23-related HL exhibit severe-to-profound high-frequency HL with only mild-to-moderate HL at low frequencies, electric acoustic stimulation (EAS) was developed to provide acoustic stimulation amplifying low-frequency residual hearing while delivering electrical stimulation through a CI to improve high-frequency hearing loss with a single device [20]. This evidence concerns the gene CDH23 and Hodgkins lymphoma.